Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.69 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.69 |
| ▸ | SPIN1 | Q9Y657 | 3/20 | 0.64 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.61 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KIF5B | P33176 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431962 | 1.00 | EHMT2 (0.69) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4426202 | 0.99 | EHMT2 (0.70) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4427357 | 0.94 | EHMT2 (0.60) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4431419 | 0.93 | EHMT2 (0.61) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4419423 | 0.93 | EHMT2 (0.61) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4423943 | 0.91 | EHMT2 (0.59) | EHMT2EHMT1SPIN1TLR9TLR7 | |
| SCHEMBL4428694 | 0.89 | SRC (0.65) | KITKDREGFRABCB11RET | |
| SCHEMBL29540227 | 0.89 | SRC (0.65) | KITKDREGFRABCB11RET | |
| SCHEMBL4422710 | 0.89 | SRC (0.65) | KITKDREGFRABCB11RET | |
| SCHEMBL2475406 | 0.87 | EHMT2 (0.64) | EHMT2EHMT1SPIN1TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |